Claims
- 1. A method of treating non-Hodgkin's B-cell lymphoma in a mammal, said method comprising concurrent therapy with an anti-CD20 antibody or fragment thereof and interleukin-2 (IL-2) or variant thereof, wherein said concurrent therapy promotes a positive therapeutic response in a treated mammal.
- 2. The method of claim 1, wherein said mammal is a human.
- 3. The method of claim 1, wherein said positive therapeutic response is greater than a therapeutic response that would be observed with therapy using said anti-CD20 antibody or fragment thereof alone or with therapy using said IL-2 or variant thereof alone.
- 4. The method of claim 1, wherein said concurrent therapy comprises administering to said mammal at least one therapeutically effective dose of a pharmaceutical composition comprising said anti-CD20 antibody or fragment thereof and at least one therapeutically effective dose of a pharmaceutical composition comprising said IL-2 or variant thereof.
- 5. The method of claim 4, wherein said IL-2 or variant thereof is administered subcutaneously.
- 6. The method of claim 4, wherein said anti-CD20 antibody is an immunologically active chimeric anti-CD20 antibody.
- 7. The method of claim 6, wherein said chimeric anti-CD20 antibody is IDEC-C2B8.
- 8. The method of claim 4, wherein said pharmaceutical composition is selected from the group consisting of a stabilized monomeric IL-2 pharmaceutical composition, a multimeric IL-2 composition, a stabilized lyophilized IL-2 pharmaceutical composition, and a stabilized spray-dried IL-2 pharmaceutical composition.
- 9. The method of claim 8, wherein said IL-2 is recombinantly produced IL-2 having an amino acid sequence for human IL-2 or variant thereof.
- 10. The method of claim 9, wherein said variant thereof has an amino acid sequence having at least about 70% sequence identity to the amino acid sequence for said human IL-2.
- 11. The method of claim 8, wherein said anti-CD20 antibody is an immunologically active chimeric anti-CD20 antibody.
- 12. The method of claim 11, wherein said chimeric anti-CD20 antibody is IDEC-C2B8 or fragment thereof.
- 13. The method of claim 4, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is in the range from about 125 mg/m2 to about 500 mg/m2 and wherein said therapeutically effective dose of IL-2 or variant thereof is in the range from about 2 mIU/m2 to about 12 mIU/m2.
- 14. The method of claim 13, wherein said therapeutically effective dose of said anti-CD20 antibody is in the range from about 225 mg/m2to about 400 mg/m2 and wherein said therapeutically effective dose of IL-2 or variant thereof is in the range from about 3 mIU/m2 to about 6 mIU/m2.
- 15. The method of claim 14, wherein said therapeutically effective dose of said anti-CD20 antibody is about 375 mg/m2 and wherein said therapeutically effective dose of IL-2 or variant thereof is about 4.5 mIU/m2.
- 16. The method of claim 4, wherein said concurrent therapy comprises a first administration of said anti-CD20 antibody or fragment thereof on day 1 of a treatment period followed by a first administration of said IL-2 or variant thereof within 7 days of said first administration of said anti-CD20 antibody or fragment thereof to said subject.
- 17. The method of claim 4, wherein said concurrent therapy comprises multiple dosing of said anti-CD20 antibody or fragment thereof and said IL-2 or variant thereof.
- 18. The method of claim 17, wherein said multiple dosing comprises administering said anti-CD20 antibody or fragment thereof once per week for a period of 4 weeks starting on day 1 of a treatment period, and administering a daily dose of said IL-2 or variant thereof for a period of 4 weeks starting on day 8 of said treatment period.
- 19. The method of claim 17, wherein said multiple dosing comprises administering said anti-CD20 antibody or fragment thereof once per week for a period of 4 weeks starting on day 1 of a treatment period, and administering said IL-2 or variant thereof on days 8, 10, 12, 15, 17, 19, 22, 24, 26, and 29 of said treatment period.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Application Ser. No. 60/192,047, filed Mar. 24, 2000, the contents of which are herein incorporated by reference in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60192047 |
Mar 2000 |
US |